Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland

benzinga.com/partner/biotech/25/10/48145433/mainz-biomed-update-early-detection-test-for-pancreatic-cancer-demonstrates-never-before-seen-res

Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer.
The…

This story appeared on benzinga.com, 2025-10-10 12:35:27.
The Entire Business World on a Single Page. Free to Use →